EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, and Biological Evaluation of Novel 3-Cyanopyridone/Pyrazoline Hybrids as Potential Apoptotic Antiproliferative Agents Targeting EGFR/BRAFV600E Inhibitory Pathways

Lamya H Al-Wahaibi, Hesham A Abou-Zied iD, Mohamed Hisham, Eman A M Beshr, Bahaa G M Youssif iD, Stefan Bräse iD, Alaa M Hayallah iD, Mohamed Abdel-Aziz

Molecules · 2023

DOI: 10.3390/molecules28186586 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Lamya H Al-Wahaibi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Sciences, Princess Nourah bint Abdulrahman University, Riyadh 11564, Saudi Arabia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah bint Abdulrahman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of novel 3-cyanopyridone/pyrazoline hybrids (21–30) exhibiting dual inhibition against EGFR and BRAFV600E has been developed. The synthesized target compounds were tested in vitro against four cancer cell lines. Compounds 28 and 30 demonstrated remarkable antiproliferative activity, boasting GI50 values of 27 nM and 25 nM, respectively. These hybrids exhibited dual inhibitory effects on both EGFR and BRAFV600E pathways. Compounds 28 and 30, akin to Erlotinib, displayed promising anticancer potential. Compound 30 emerged as the most potent inhibitor against cancer cell proliferation and BRAFV600E. Notably, both compounds 28 and 30 induced apoptosis by elevating levels of caspase-3 and -8 and Bax, while downregulating the antiapoptotic Bcl2 protein. Molecular docking studies confirmed the potential of compounds 28 and 30 to act as dual EGFR/BRAFV600E inhibitors. Furthermore, in silico ADMET prediction indicated that most synthesized 3-cyanopyridone/pyrazoline hybrids exhibit low toxicity and minimal adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansStructure-Activity RelationshipProto-Oncogene Proteins B-rafMolecular Docking SimulationCell ProliferationErbB ReceptorsDrug Screening Assays, AntitumorCell Line, TumorProtein Kinase Inhibitors

Stichwörter der Autor:innen

anticancerapoptosisdockingpyrazolinepyridinesynthesis

Substanzen

Proto-Oncogene Proteins B-rafAntineoplastic AgentsErbB ReceptorsProtein Kinase InhibitorsBRAF protein, humanEGFR protein, human

Autor:innen und Institutionen

  • Department of Chemistry, College of Sciences, Princess Nourah bint Abdulrahman University, Riyadh 11564, Saudi Arabia.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Deraya University, Minia 61111, Egypt.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
  • Institute of Biological and Chemical Systems, IBCS-FMS, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Sphinx University, Assiut 71515, Egypt.

ORCID-Profile: Hesham A Abou-Zied, Bahaa G M Youssif, Stefan Bräse, Alaa M Hayallah

Förderung

  • Princess Nourah bint Abdulrahman University

Zitieren

APA

Al-Wahaibi, L. H., Abou-Zied, H. A., Hisham, M., Beshr, E. A. M., Youssif, B. G. M., Bräse, S., Hayallah, A. M., & Abdel-Aziz, M. (2023). Design, Synthesis, and Biological Evaluation of Novel 3-Cyanopyridone/Pyrazoline Hybrids as Potential Apoptotic Antiproliferative Agents Targeting EGFR/BRAFV600E Inhibitory Pathways. Molecules. https://doi.org/10.3390/molecules28186586

Vancouver

Al-Wahaibi LH, Abou-Zied HA, Hisham M, Beshr EAM, Youssif BGM, Bräse S, et al. Design, Synthesis, and Biological Evaluation of Novel 3-Cyanopyridone/Pyrazoline Hybrids as Potential Apoptotic Antiproliferative Agents Targeting EGFR/BRAFV600E Inhibitory Pathways. Molecules. 2023. doi:10.3390/molecules28186586

BibTeX
@article{AlWahaibi2023,
  author = {Al-Wahaibi, Lamya H and Abou-Zied, Hesham A and Hisham, Mohamed and Beshr, Eman A M and Youssif, Bahaa G M and Bräse, Stefan and Hayallah, Alaa M and Abdel-Aziz, Mohamed},
  title = {Design, Synthesis, and Biological Evaluation of Novel 3-Cyanopyridone/Pyrazoline Hybrids as Potential Apoptotic Antiproliferative Agents Targeting EGFR/BRAFV600E Inhibitory Pathways},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28186586}
}
Kostenlos starten →